IJBPAS, December, 2025, 14(12): 6546-6570

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

REVIEW ON REGULATORY CONSIDERATIONS FOR PAEDIATRIC DRUG DEVELOPMENT AND CHALLENGES IN PAEDIATRICS

SHYAM B AND KAMARAJ R*

Department of Regulatory affairs, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur – 603 203, Tamil nadu, India

***Corresponding Author: Dr. Kamaraj R: E Mail:** kamarajar@srmist.edu.in

Received 19th Sept. 2024; Revised 25th Oct. 2024; Accepted 13th Dec. 2024; Available online 1st Dec. 2025

https://doi.org/10.31032/IJBPAS/2025/14.12.9646

ABSTRACT

Paediatric drug development presents a distinct set of challenges, ranging from economic constraints and formulation complexities to ethical considerations and regulatory hurdles. Economic constraints establishing from smaller market sizes and prolonged development timelines discourage investment in this specialized field. This review charts the evolution of paediatric drug regulations in the United States and Europe, focusing on landmark legislative measures like the paediatric Labelling Rule, the Best Pharmaceuticals for Children Act (BPCA), and the Paediatric Research Equity Act (PREA). These regulatory frameworks have incentivized pharmaceutical companies to undertake paediatric trials, thereby enhancing the safety and labelling standards of medications prescribed to children. The selection of excipients in paediatric formulations demands challenges consideration to ensure both safety and palatability, given the heightened sensitivity of young patients. Selection of dosage forms to suit age-specific requirements further complicates drug formulation and design, posing additional challenges. Ethical considerations play a pivotal role, necessitating stringent protocols for informed consent and ensuring protections for vulnerable paediatric populations. Scientifically, the unique pharmacokinetic and pharmacodynamics profiles in children mandate precise dosing strategies and formulation adjustments, increasingly supported by advanced Modelling and Simulation (M&S) techniques. As the field progresses, collaborative efforts and innovative methodologies are crucial to advancing paediatric therapeutics, ensuring safe and

efficacious treatments for young patients worldwide. Efforts to streamline regulatory processes, coupled with advances in telemedicine and biomarker utilization, promise to bolster paediatric medication development, thereby enhancing healthcare outcomes for paediatric populations worldwide.

Keywords: Paediatric drug development, formulation complexities, Paediatric Labelling Rule, Best Pharmaceuticals for Children Act (BPCA), Paediatric Research Equity Act (PREA), telemedicine

INTRODUCTION:

Developing pharmaceuticals for paediatric patients is a difficult task filled with ethical, scientific, operational, and financial constraints. Children and adolescents represent a diverse range than adults, with distinct medical demands, biological components, and physiological traits. This variability emphasizes the complexities of paediatric care, demonstrating that paediatric populations cannot be regarded as a homogeneous group[1]. Paediatrics is the branch of medicine that cares for a patient's physical, social, and mental health from infancy to late adolescence **[2]**. As per the "International Council for Harmonisation" (ICH) subject E11 (CPMP/ICH/2711/99) and the ICH E11(R1), the paediatric populace can be isolated into a few categories: preterm infant new-born children (born between the day of birth and the expected date of birth, besides,27 days), term and post-term new-born children (born between 0 and 27 days), new-born children, and little children (born between 28 days and 23 months), children (born between 2 and 11 years old), and adolescents (born between 12 and 16–18 years old, depending on the region) **[1]** . Pharmaceutical companies have a number of difficulties while developing drugs for paediatric patients. The preparation and execution of a paediatric study require extra care because the patient group is more susceptible. Clinical studies for adults and children are not the same. There are several practical and ethical factors, with the latter receiving special focus in the regulatory guidance materials. The primary challenges that arise from this are defining the initial dosage in children, selecting suitable sampling plans, selecting appropriate techniques for data collection and analysis, producing information regarding a drug's safety, effectiveness, pharmacokinetics, and pharmacodynamics in children, and, finally, figuring out the appropriate dosage and schedule. Translating dose forms and dosage strengths directly from adults to children is unsuitable due to the impact on the pharmacokinetics (PK) and pharmacodynamics (PD) of the active pharmaceutical ingredients (API) **[3].**

Modelling and Simulation (M&S) techniques serve as invaluable instruments for refining trial designs and augmenting insights derived from paediatric research Physiologically, children undergo rapid growth and development, leading to age-related differences in metabolism, organ function, and drug responses compared to adults. These variations require careful consideration in dosing, formulation, and safety assessments to avoid under- or over-treatment and mitigate potential long-term effects. Ethically, conducting clinical studies in paediatric populations raises unique considerations regarding informed consent, vulnerability, and the balance between therapeutic benefits and risks. Ensuring that research protocols prioritize the welfare of children while obtaining robust scientific data is essential but often complex. The regulations aim to safeguard children from potential harm while promoting the availability of medicines customized to their needs, yet they add layers of complexity to the drug development process. Addressing these challenges demands innovative methodologies, collaborative efforts among stakeholders, and a deep commitment to paediatric health to advance the development of safe and efficacious medicines for children. The two agencies work closely together to improve coordination and increase the likelihood that paediatric pharmaceutical development will take place globally. Before exploring the region-specific advice contained on the pertinent pages of the FDA and EMA websites, this is intended to be a preliminary reading. This review provides an overview of paediatric drug development regulations and challenges, as well as scientific concerns for clinical research in children. The discussion of using M&S to extract knowledge from data will conclude the process of organizing, conducting, and evaluating paediatric studies

2. HISTORICAL PERSCEPTIVES IN PAEDIATRIC DRUG REGULATIONS

Paediatric Drug Regulations in USFDA:

In the past, paediatric patients have only been involved in a small percentage of all marketed pharmaceuticals' clinical trials, and the majority of marketed drugs were not intended for use in paediatric patients. As a result, many medications were given to kids off-label without proper Knowledge of the right dosage, safety, or effectiveness **[4]**. The first step was taken in 1994 with the issuance of the Paediatric Labelling Rule **[5]**, which required pharmaceutical companies to assess the data that was already available and decide if it was adequate to support the inclusion of additional information about paediatric use in the drug's label. According to the Paediatric Labelling Rule, a manufacturer must file an additional new drug application

(NDA) with the FDA requesting a change to the label's paediatric use information if the maker believes that the data currently available allows for such a change **[6]**. The FDA described and finalized the Paediatric Labelling Run the show in 1997 and 1998, since the approach under the Paediatric Labelling Run the show was completely purposeful and did not entirely move forward the number **[7]**. The purpose of the rule was to guarantee that, at the time of, or shortly after, approval, new pharmaceuticals and biological products that are likely to be used frequently in children or that offer a significant therapeutic advantage over currently available treatments for children have appropriate paediatric labelling for the approved indication. Prior to the approval of a new drug, regulatory requirements necessitate that the manufacturer provide comprehensive safety and efficacy data specific to the indicated uses across relevant paediatric age groups. The Paediatric drug legislation/regulations is shown below in **Table 1**.

The Food and Drug Administration Modernization Act (FDAMA), which was passed in 1997, also instituted a process whereby the FDA would create a list of drugs for which further paediatric data may be helpful, determine which studies are required, and then send sponsors a written request (WR) for paediatric studies. The Paediatric drug regulations in the USA is shown in **Figure 2**. The WR specifies when these studies must be finished. Furthermore, the FDAMA gave pharmaceutical companies an incentive to research medicines that would help paediatric patients' health. Companies that produced research in response to a WR received an additional six months of marketing exclusivity [**8**]. The milestones of paediatric legislation in US is shown in **Figure 2**.

Table 1: Paediatric drug legislation/regulations

AGENCY	Paediatric Drug Regulations	Decision body	Official Website
USFDA	Best Pharmaceuticals for children Act (BPCA)	FDA Review Division (PeRC advisory)	https://www.federalregister.gov/documents/2019/04/23/2019-08167/best-pharmaceuticals-for-children-act-bpca priority-list-of-needs-in-paediatric-therapeutics
	Paediatric Research Equity Act (PREA)	FDA Review Division (PeRC advisory)	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-comply-pediatric-research-equity-act
EMA	Regulation 1901/2006	EMA after opinion from PDCO (Paediatric committee)	https://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2006R1901:20070126:EN:PDF



Figure 1: Paediatric Drug Regulations in the US



Figure 2: Milestones of paediatric legislation in the US

THE BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA):

In 2002, Congress reauthorized the BPCA legislation, thereby extending the NIH BPCA Program for a subsequent five-year period. The updated legislation also grants the NIH the authority to prioritize research aimed at identifying biomarkers relevant to paediatric diseases and conditions **[8]**. USFDA's Regulatory Procedure under BPCA is mentioned in **Figure 3**.

Bpca: Incentives

The BPCA introduces a voluntary incentive program whereby pharmaceutical sponsors may receive market exclusivity in return for conducting paediatric studies specified in a Written Request (WR) issued by the FDA. This initiative aims to encourage

pharmaceutical companies to allocate resources towards paediatric drug development by granting them exclusive marketing rights for a defined period, subject to meeting the FDA's criteria for conducting these studies **[9]**.



Figure 3: USFDA's Regulatory Procedure under BPCA [8]

PAEDIATRIC MARKETING EXCLUSIVITY:

Exclusivity is granted contingent upon several criteria:

- The manufacturer must fulfil and submit reports on studies specifically requested by the FDA.
- These studies are mandated to encompass appropriate drug formulations designed for different age groups.
- Any approved labelling modifications resulting from these studies must be implemented within specified timelines.

Legally, manufacturers are required to propose labelling made to children based on the outcomes of these studies. Applicants pursuing paediatric marketing exclusivity

must additionally provide adverse event reports related to the drug post-marketing alongside their study submissions **[10]** .Paediatric marketing exclusivity constitutes an additional benefit beyond existing exclusivity or patent protection . Generally, products lacking residual patent lifespan or exclusivity do not qualify for this provision **[11]**.

PAEDIATRIC RESEARCH EQUITY ACT (PREA)

The PREA established a statutory foundation for various components of the Paediatric Rule. This law mandated the inclusion of paediatric assessments in certain drug applications, unless exemptions or deferrals were granted. Furthermore, it obligated sponsors to furnish a paediatric plan delineating the methodology for conducting these assessments, specifying timelines, and discussing the creation of formulations appropriate for usage in children **[12]**. PREA mandates the inclusion of paediatric assessments in NDAs and BLAs for new pharmaceutical components, dosage formulations, dosing regimens, indications, and administration routes, unless a waiver or deferral has been obtained by the manufacturer. The Pie chart representation of paediatric labelling changes from 1998 – 2023 is mentioned in **Figure 5**.

PAEDIATRIC REVIEW COMMITTEE (PERC):

The FDA Amendments Act established the PeRC, a closed committee, to oversee BPCA and PREA-related operations. In order to promote uniformity and quality, the framework for preparing consultations and evaluations of data, planning, and research is provided by the PeRC Every WR, waiver, deferral, and study submitted in response to a WR is reviewed by it.

INVESTIGATIONAL PAEDIATRIC STUDY PLAN (IPSP):

The iPSP assessment procedure outlines specific timelines and requirements mandated under the PREA (Paediatric Research Equity Act). Upon completion of Phase 2 clinical trials, a sponsor must submit the iPSP no later than 60 calendar days following the end-of-Phase 2 meeting. If a Phase 3 study or a combined Phase 2 and 3 study is not planned or will be conducted without an Investigational New Drug (IND) application, the iPSP submission deadline is set at 210 calendar days before filing a marketing application or supplement. Submission of the iPSP should be directed to the appropriate review division within the Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER), depending on the nature of the drug under consideration. For drugs not yet under an active IND but intended for initial Phase 3 studies, the iPSP should be submitted as a pre-IND package. Following the iPSP submission, the FDA

undertakes a 90-day review period, during which it may convene its internal Paediatric Review Committee (PeRC) for consultation. Subsequently, the sponsor is allotted an additional 90 days to review**.** The Timelines for iPSP Submission is mentioned in **Figure 4**. Within this timeframe, the sponsor must finalize an agreed iPSP. The FDA then has 30 days following receipt of the finalized iPSP to issue formal correspondence confirming agreement or detailing any areas of disagreement. In cases where agreement is not reached, the iPSP is categorized as non-agreed. Overall, the iPSP review process is designed to conclude within 210 days from submission,

.



Figure 4: Timelines for iPSP Submission



Figure 5: Pie chart representation of paediatric labelling changes from 1998 - 2023

Procedure for approving Paediatric drugs in US:

Non clinical research (animal and in vitro manufacturing)

↓ File an IND with the FDA. FDA examines suggested clinical protocol and nonclinical data.Sponsor and FDA concur on a protocol.

Phase 1 clinical trials typically involve a small number of participants who are healthy

↓ FDA assesses the safety of Phase 1 data evaluates suggested Phase 2 protocol (s).

Phase 2 trial: Safety, dosage, and initial efficacy assessments

↓ FDA examines phase two results. FDA examines suggested phase 3 procedures. Sponsor and FDA concur on the suggested phase 3 protocol(s).

Phase 3 trials (Full evaluation of safety & efficacy)

↓ For an NDA or BLA, the FDA examines all manufacturing, preclinical, and clinical data choices about PREA compliance and any post-marketing safety investigations

NDA/BLA approval, and Labelling

↓



Figure 6: The US paediatric medication approval pathway [8]

INVESTMENTS IN PAEDIATRIC DRUG DEVELOPMENT AND MARKET TRENDS

Concurrently, the market for paediatric pharmaceuticals is expected to expand between 2023 and 2028, from USD 120.31 billion to USD 179.74 billion, indicating a Compound Annual Growth Rate (CAGR) of 8.36% throughout the projection period. This projected growth is attributed to several factors, notably an increasing birth rate in comparison to earlier years and the ongoing occurrence of serious paediatric illnesses that raise the risk of childhood death. Pneumonia, diarrhoea, malaria, premature birth, and problems during childbirth remain the leading causes of death for children under five worldwide. As per the 2020 report released by UNICEF, the United Nations Children's Emergency Fund, 2020 saw the death of 5.0 million children under the age of five, highlighting the critical need for affordable treatments and supportive policies. It is acknowledged that the field of paediatric research is unstable and that there are many unknowns about its future. However, since 2000, the National Institutes of Health (NIH) has made strategic investments in paediatric research a priority, as seen by the rise in funded projects and funding, though 2011 saw some volatility (**see Figure 7**) **[13]**.



Figure 7: Overview of the granted projects (green bars) and the financial support (blue line) sponsored by the National Institutes of Health (NIH) that address the paediatric population, between 2000 and 2nd August 2023 [13]

PAEDIATRIC DRUG REGULATIONS IN THE EU

In 1997, the European Commission convened a round table to address issues related to paediatric medicines at the European Medicines Agency (EMA). This meeting highlighted the necessity to enhance legislation, particularly through the implementation of incentive systems **[14]** The Milestones of paediatric legislation in the EU is mentioned in **Figure 8**.The following year, in 1998, the Commission advocated for international collaboration regarding the conduct of clinical trials involving children within the framework of the International Conference of Harmonisation (ICH) **[15]**. This activity driven to the advancement of the harmonized tripartite E11 ICH rule titled "Clinical examination of restorative items in the paediatric populace," which was finalized in 2000 **[16]**. It subsequently became a European guideline in 2001. By December 2000, recognizing the urgency of addressing the use of unauthorized medicinal products in paediatric populations, the European Health Council urged the Commission to take specific actions. As a response, the Commission published a consultation paper titled "Better medicines for children proposed regulatory actions on paediatric medicinal products" in 2002.In December 2006, the European Union endorsed the adoption of new legislative measures, which were enacted in January 2007. This regulatory framework was designed to tackle enduring issues concerning the accessibility, effectiveness, and safety of pharmaceuticals intended for paediatric populations.



Figure 8: Milestones of paediatric legislation in the EU

Paediatric Committee (PDCO):

The (PDCO) **[17]**, pronounced "pedco," serves as the European Union's counterpart to the Paediatric Review Committee (PeRC) in the United States. Composed of experts proficient in the development and evaluation of various facets of paediatric medicinal products, The committee comprises five members and substitutes from the Committee for Medicinal Products for Human Use (CHMP), along with one member and substitute from each EU Member State not otherwise represented in the CHMP, as well as six members and substitutes appointed by the European Commission to represent healthcare professionals and patient organizations.

The primary mandate of the PDCO is to evaluate the content of Paediatric Investigation Plans (PIPs) submitted by sponsors and issue opinions in accordance with EU regulations governing paediatric medicines. This responsibility includes assessing applications for full or partial waivers and deferrals.

PAEDIATRIC INVESTIGATION PLAN (PIP) [18]: A Paediatric Investigation Plan (PIP) forms the foundational framework for the development and approval of medicinal products intended for specific subsets of the paediatric population, delineated by various age groups. It is required to be submitted once pharmacokinetic studies in adults are available, typically in the early stages of a new compound's development, typically after Phase 1 clinical trials. The PIP must undergo approval or amendment by the Paediatric Committee (PDCO) and carries legal binding for the sponsoring company. If new information becomes available throughout the development process, the company has the option of requesting changes to the originally agreed-upon PIP from the PDCO.A waiver may be issued for specific age groups or all age groups under certain circumstances. The Paediatric investigation procedure is shown in **Figure 9**. The European Medicines Agency (EMA) offers comprehensive details regarding the Paediatric investigation Plan procedure on its official website, which includes guidelines outlining the required format and content of PIPs **[19]**. Information pertaining to EMA determinations regarding PIPs, including decisions on waivers, is disclosed to the public following the removal of commercially sensitive data.



Figure 9: Paediatric Investigation Plan: Assessment procedure



Figure 10: The approval pathway of Paediatric drugs in the EU

REWARDS AND INCENTIVES:

In accordance with regulatory guidelines, it is required to submit paediatric data as stipulated in an agreed Paediatric Investigation Plan (PIP) for all regulatory submissions of new products and for products still under patent during requests for line extensions, unless granted a waiver or deferral. Upon receiving authorization across all European Union (EU) Member States and including study outcomes in the product information, even in cases where results are negative, the medication qualifies for a six-month extension of patent exclusivity. Orphan-designated medicinal products adhere to similar mandates and additionally benefit from two years of market exclusivity beyond the standard 10-year exclusivity granted under the EU Orphan Regulation. A compliance evaluation with the agreed-upon PIP is required before accessing any incentive or gaining marketing authorization **[20] [21]**.

PAEDIATRIC USE MARKETING AUTHORISATION (PUMA)

A Paediatric Use Marketing Authorisation (PUMA) is granted by the European Medicines Agency (EMA) for medications specifically intended for paediatric use, meaning they are designated for patients under 18 years of age. Similar to standard EMA marketing authorizations, PUMA approvals are valid throughout the countries within the European Economic Area. The issuance of a PUMA requires adherence to a Paediatric Investigation Plan (PIP) that has been agreed upon by the Paediatric Committee (PDCO). Consequently, data utilized in PUMA-approved drugs is protected for a period of 10 years, and applications benefit from partial exemption from fees **[22]**. The Paediatric Regulation introduced this type of authorization for medicines that meet specific criteria: they must be existing drugs without Supplementary Protection Certificate (SPC) or patent protection eligible for SPC, and they must be exclusively intended for paediatric use.

GENERAL CONSIDERATIONS:

A. Ethical and regulatory framework:

Paediatric populations are considered vulnerable, requiring special protections in research and clinical trials. Informed consent processes involve parents or guardians and, where appropriate, assent from children. Regulatory agencies (e.g., FDA in the US, EMA in Europe) provide specific guidelines for paediatric drug development, including requirements for safety, efficacy, and age-appropriate formulations.

B. Age categories:

The age categories are used to ensure that medications are studied in appropriate paediatric populations, taking into account differences in pharmacokinetics, pharmacodynamics, safety profiles, and

developmental considerations across different stages of childhood and adolescence. Regulatory agencies provide specific guidance on how to design clinical trials, assess safety and efficacy endpoints, and formulate medications suitable for each age category within paediatric populations. This structured approach aims to optimize therapeutic outcomes while ensuring the safety of paediatric patients receiving medications.

C. Determination of paediatric dose:

Paediatric dose determination often involves computing a portion of the dosage for adults. Scaling by body surface area or body weight in milligrams per kilogram was a popular technique **[23]**. Allometric scaling, like the "3/4 Rule," was often applied to extrapolate adult doses or clearances to children **[24]** .These scaling techniques are simple, quick, and effective. Depending on the medication, they might also yield a trustworthy paediatric dose estimate. As a result, they ought to be limited to standardizing dosage or clearance for kids older than two. Paediatric dose calculation can be greatly aided by modelling and simulation (M&S) techniques such as physiologically based pharmacokinetic (PBPK) modelling and population PK/PD modelling. Additionally, a suitable safety factor should be applied to the desired therapeutic dose in order to estimate the starting dose. One strategy would be to start dosing in a small group (n = 4–6) and evaluate PK, PD, and/or safety. Therefore, it is best to start with older age groups and use data adaptively to potentially change doses for following trials in younger age groups if numerous studies with different age ranges are planned in the paediatric population.

D. Paediatric Formulations:

When giving medication to children, the oral route is often chosen. To meet the needs of different age groups, a variety of formulation alternatives are required, such as liquid and solid oral dosage forms. For younger children who have trouble swallowing tablets or capsules, liquid versions are very helpful. Parenteral formulations are often used in new-borns; therefore, careful attention to medication concentrations and excipient selection is necessary to guarantee safety. Paediatric Investigation Plans (PIPs) must include methods to change medication formulations to improve acceptability, convenience of use, safety, and efficacy across various paediatric demographic subgroups, according to a regulation from the European Medicines Agency (EMA). The EMA's "Formulations of Choice for the Paediatric Population" **[25]** reflection paper does not function as regulatory guidance dictating particular specifications. Rather, it provides insightful advice.

E. Pk sampling and pk evaluation in paediatrics:

Children undergo rapid developmental changes in organ function, body composition, and metabolism compared to adults. These differences affect drug absorption, distribution, metabolism, and excretion (ADME). Age-specific PK/PD studies are crucial to understanding dosing requirements, safety margins, and therapeutic efficacy across different paediatric age groups (neonates, infants, children, and adolescents).

F. Clinical trial design:

Designing trials that balance the need for evidence with ethical considerations, such as placebo use and minimizing risks. Choosing appropriate endpoints (e.g., clinical outcomes, biomarkers) relevant to paediatric populations and reflective of treatment benefits.

CHALLENGES IN PAEDIATRIC DRUG DEVELOPMENT:

A. Financial Strain

The process of developing new drugs takes a long time, costs a lot, and has little chance of success—that is, becoming approved for sale. The economic challenges have gotten more intense over the past few decades, as expenses associated with research and development have been rising while the number of successfully commercialized goods has been declining. Economic factors provide a significant obstacle to paediatric research because the benefits offered by the paediatric market are even less attractive than the work involved. The following are significant elements that contribute to the economic challenges and consequent lower profitability of paediatric investigation: The market's size is significantly reduced by the following factors: a small patient population that is further divided into multiple subgroups; inadequate infrastructures that impede prompt and economical PCT performance, such as appropriately GCP-trained paediatric investigators, investigation sites, centralized laboratories, and contract.

B. Excipients:

As per the WHO working document on the development of paediatric medications, When selecting excipients for a paediatric formulation, it is important to take into account many factors, such as the target age group's safety, the method of administration, and the frequency, duration, and dosage of treatment **[26]**. Although there are greater risks associated with liquid formulations, in general, fewer excipients should be utilized in paediatric formulations because the safety data for younger children is either lacking or very limited. Colouring agents and antimicrobial preservatives should be avoided at all costs because they frequently have the potential to be poisonous and allergic. For example, solid ingredients should be preferred over liquid ones in imitations. The potential adverse effects of sweeteners, such as carcinogenicity, should

be taken into account. Effects such as laxatives, glucose surges in diabetics, inflammatory responses in fructose intolerant people, etc.

C. Dosage Forms:

Quality and dose shapes of paediatric drugs are vital perspectives to guarantee an exact and reasonable organization of treatment. An optimal formulation should support many dose forms or strengths of an API in a ready-to-use shape that is optimally adjusted based on an age-specific need. It is recommended to try a minimum dose frequency and to choose for Patients enrolment and retention with extended release over those with immediate release.

D. Pilot program for novel excipients:

The use of novel excipients raises difficulties due to the lack of a specific approval procedure. Currently, approval of new excipients is dependent on their use in a specific drug formulation, a procedure which often discourages drug researchers from using novel excipients due to regulatory concerns. The Centre for Drug Evaluation and Research (CDER) at the FDA has initiated a pilot program aimed at evaluating novel excipients. This initiative is supported by BASF and Senopsys. According to Worthington, advancements in pharmaceutical technologies and excipients often originate from the food industry. Technologies such as co-processing and sustained-release systems for flavours and sweeteners, akin to those employed in confectionery and chewing gum products, hold potential for enhancing drug formulations, particularly those containing Active Pharmaceutical Ingredients (APIs) with persistent aftertastes, such as clarithromycin and others. However, the development of such excipients has been impeded by the prolonged approval process currently in place.

E. Long Development Timelines:

Delays in study initiation and completion due to recruitment challenges, regulatory approvals, and the need for long-term follow-up to assess safety and efficacy. Shorter market exclusivity periods post-approval compared to adult drugs, impacting return on investment**.**

F. Paediatric drug delivery:

The selection and preparation of appropriate pharmaceutical dosage forms for administering medications to paediatric patients present considerable challenges, as there is no universally applicable solution **[27]**. Pharmaceutical dosage forms are categorized based on their type and intended route of administration **[28]** . Additionally, minimizing dosing frequency is important to ensure adherence to the dosing schedule by caregivers and older children. Therefore, various oral dosage forms have been developed and studied, including solid forms such as tablets, capsules, orodispersible formulations, powders for

reconstitution, and chewable tablets, as well as liquid forms such as solutions, suspensions, elixirs, and syrups **[28]**. When designing oral dosage forms, it is crucial to consider age-related differences in gut function and health status. Liquid dosage forms are preferred, particularly for children under 5 years old, due to ease of swallowing and dose adjustment. However, many liquid forms are not labelled for paediatric use, and those that are labelled may not be available in appropriate formulations. To address these challenges, tablets or capsules may be used to prepare liquid or powder forms "especially" or "extemporaneously." However, this approach carries risks of dosing errors due to improper division or dispensing, which is particularly critical for antibiotics widely prescribed to paediatric patients.

G. Small Market Which Leads To Low Profitability:

Pharmaceutical companies have historically prioritized developing treatments for adult indications due to the complex logistical and ethical challenges associated with conducting clinical trials in paediatric populations. However, there is a growing recognition of the need to develop therapies specifically tailored for children and to enhance understanding of how children respond to various diseases **[29]**. In addition to ethical considerations, there exists a significant economic barrier. Pharmaceutical companies have been reluctant to invest in paediatric drug development primarily due to the comparatively limited market size, which diminishes potential financial returns. Paediatric drug development has various challenges, including methodological and ethical criteria unique to paediatric trials, significant research costs, and a limited and diversified market. These challenges have resulted in limited efforts to adapt medications to meet the specific needs of children. Even when paediatric medicines are approved, they may not always be suitable for younger children and neonates in terms of dosing, appropriate dosage forms, and excipients **[31]**.

H. Patient enrolment and retention:

Patient enrolment and retention in paediatric clinical trials (PCTs) present significant challenges that profoundly influence study design and completion. Low enrolment and high withdrawal rates among eligible paediatric subjects, driven by epidemiological factors and concerns among patients' families regarding potential trial risks, contribute to incomplete study cohorts. This shortage of participants often necessitates the involvement of multiple investigational sites to meet the required enrolment targets. While this approach enhances the likelihood of achieving sufficient participant numbers, it concurrently prolongs the timeline,

increases workload, and escalates costs associated with obtaining regulatory approvals across diverse geographic locations.

I. Ethical issues:

Ethical considerations in paediatric clinical research are integral to the complex process of conducting trials involving children. These ethical implications form the foundation of regulatory frameworks established to govern such research, although some areas remain ambiguous and are continuously refined and implemented. Moreover, when research involving children is necessary, priority should be given to including the least vulnerable subgroups. Unnecessary duplication of trials in paediatric populations is also deemed unethical. In a broader context, paediatric clinical trials are expected to adhere to the 'Belmont principles', which include beneficence (acting in the best interest of participants and avoiding harm), justice (fair distribution of the burdens and benefits of research), and respect for persons. Additionally, these trials should align with the four principles of healthcare ethics: autonomy, beneficence non-maleficence and justice **[32].**

J. Data security and the preservation of biological samples:

Data protection for children is primarily concerned with potential future usage after the trial ends. Personal information, including sexuality and illicit substance consumption, as well as biological samples, are gathered and held for long periods of time. There is a requirement for careful data protection. Consent is required for material retention (which must be reconfirmed whenever the child reaches adulthood), and confidentiality is assured

K. Biological specimens:

Biological specimens are frequently required in clinical trials to gather essential data from patients. The collection of blood, in particular, necessitates careful ethical consideration to minimize discomfort or pain for the child. From a clinical perspective, there are strict limitations on the volume of blood (and other biological samples) that can be safely withdrawn from a child **[33]**. According to recommendations outlined in a 2008 document, which has been recently revised by a specialized group tasked with developing guidelines for Directive 2001/20/EC, trial-related blood loss should not exceed 3% of the total blood volume over a period of 4 weeks, nor should it exceed 1% at any single time **[34]**. These guidelines are crucially evaluated during trial design and can influence the acceptance or rejection of study protocols by the ethics committee responsible for regulatory approval.

L. Prediction of bitterness is a major concern:

The prediction of bitterness is a major topic in current research and development activities. Overcoming this unfavourable taste experience is an important issue, as is predicting whether newly produced chemicals would be bitter, as Assis points out. Despite these challenges, recent advances have significantly enhanced the detection of bitter Active Pharmaceutical Ingredients (APIs).Assis highlights the importance of Bitter DB as a resource for formulation specialists, containing over 1000 naturally occurring and manufactured bitter chemicals **[35]**. Machine learning systems trained on these existing bitter APIs can predict bitterness in novel chemicals. Such predictions, together with detailed physiochemical assessments of APIs, enable pharmaceutical formulators to proactively pick relevant taste-masking technologies.

M. Palatability a primary challenge:

Regulatory directions require pharmaceutical companies to develop drugs for certain age groups. Senopsys President and Founder Jeff Worthington notes that obtaining palatability for oral dosage forms such as solutions, suspensions, orally disintegrating tablets, and multiparticulates (including powders, granules, and minitablets) continues to be a significant problem. Children place a high value on flavour, as demonstrated by a survey done by the American Association of Paediatrics in 2023, which identified disagreeable taste as a key barrier to adherence among paediatric patients. According to Assis, acceptability, palatability, and convenience of administration by caregivers have a substantial impact on a child's desire to take medicine. Hopper adds that palatability includes taste, pill size, pH, texture, and liquid formulation volume. According to Worthington, many medications include bitterness or other disagreeable sensory features such as malodor and discomfort, which necessitate diverse mitigation strategies due to different perception pathways. He argues that, while several technologies exist for controlling slightly to moderately bitter chemicals, excessively bitter drug actives may necessitate advanced approaches such as particle coating, complexation, encapsulation, or other tactics to protect the API from taste receptors.

For bitter APIs, Schäfer advises formulators to neutralize taste appeal in paediatric formulations, ensuring they lean towards neutrality rather than sweetness.

N. Overcoming swallowing issues:

Addressing swallowing issues is a critical challenge in paediatric drug formulation, involving the development of attractive alternatives to improve convenience and compliance. Worthington recognizes that ensuring palatability and ease of swallowing is a constant concern for not only paediatric patients, but also elderly and special needs

populations.

Dosage forms that are simpler to swallow increase exposure to oral cavity receptors, particularly gustatory (taste buds), olfactory (smell receptors), and chemoreceptors (sensitivity to irritants). According to Worthington, these novel formulations frequently provide greater palatability issues than traditional pills and capsules. According to Assis, discovering suitable taste-masking solutions to effectively attenuate unpleasant sensations and hence enhance patient adherence remains a key field that requires additional research and improvement. Hopper emphasizes the need of increasing flavour masking strategies with efforts to improve.

5. FUTURE PERSPECTIVE:

The regulatory landscape are expected to undergo major modifications in the field of paediatric medication development in the future. In recent times, telemedicine has gained popular as a unique way of providing paediatric healthcare. Families that live in remote places or have limited access to healthcare services will find healthcare more easy and accessible thanks to telemedicine, which enables healthcare providers to communicate with patients and their families remotely. Moreover, increasing focus is being placed on optimizing the use of paediatric biomarkers and improving pharmacokinetic /pharmacodynamics models. These developments are intended to optimize paediatric medication therapy by facilitating more accurate dose selection and prediction of safety and efficacy data across various age groups and developmental stages. Global collaboration amongst regulatory bodies is planned to standardize protocols and accelerate the approval of data from paediatric studies conducted worldwide. Furthermore, it is projected that providing incentives for paediatric medication development—like prolonged market exclusivity, regulatory fee waivers, and targeted research grants—will encourage more funding and innovation in this crucial field of medicine. In the end, these forward-looking views highlight how crucial it is to combine scientific progress with strict regulatory monitoring in order to promote paediatric medication development. The main objective is to guarantee the accessibility of safe, efficient, and developmentally appropriate treatments that successfully meet the special medical requirements of paediatric populations throughout the world.

CONCLUSIONS:

Developing medications specifically for paediatric populations poses unique challenges. In future, pharmaceutical companies may benefit from increased incentives aimed at promoting the paediatric drugs, thereby the patients will get their medications in affordable prices. Moreover, the regulatory challenges could lead to more

flexible testing requirements, facilitating expedited drug development timelines without compromising safety standards. The ultimate goal is to simplify the development process and also improving accessibility to child-specific drugs that are both safe and effective. There are still many challenges to be solved which involves the development of age-appropriate medications, logistical difficulties in recruiting paediatric trial participants, and ethical concerns. However, with further progress in regulatory policies and cooperative efforts, the future will have a strengthening paediatric healthcare outcomes with more accessible and efficient pharmaceutical development.

ACKNOWLEDGEMENT:

Author wants to acknowledge the management of SRM College of Pharmacy, SRM Institute of Science and technology for their valuable support.

CONFLICT OF INTEREST: Authors declare no conflict of interest

REFERENCES:

[1] Domingues C, Jarak I, Veiga F, Dourado M, Figueiras A: Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies. Pharmaceutics. 2023, 15:2431. 10.3390/pharmaceutics15102431

[2] Ernest TB, Elder DP, Martini LG, Roberts M, Ford JL: Developing paediatric medicines: identifying the needs and recognizing the challenges. Journal of Pharmacy and Pharmacology. 2010, 59:1043–55. 10.1211/jpp.59.8.0001

[3] Turner MA, Catapano M, Hirschfeld S, Giaquinto C: Paediatric drug development: The impact of evolving regulations. Advanced Drug Delivery Reviews. 2014, 73:2–13. 10.1016/j.addr.2014.02.003

[4] Blumer JL: Off-label uses of drugs in children. Pediatrics. 1999, 104:598–602.

[5] Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration Guidance for Industry: The Content and Format for Pediatric Use Supplements.

[6] History of Paediatric Studies, Rule, Legislation and Litigation: https://www.bio.org/advocacy/letters/history-pediatric-studies-rule-legislation-and-litigation.

[7] Department of Health and Human Services, Food and Drug Administration Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients; Final Rule. 2010**.**

[8] Sowmya VS, Manjulatha YB, Indusekhar JNB, Raju VB: A

Comparative Review on the Regulatory Framework of Pediatric Drugs in the US and EU: Challenges and Recommendations. Int J Drug Reg Affairs. 2023, 11:74–86. 10.22270/ijdra.v11i4.635

[9] Susan T.: FDA's Authority to Ensure That Drugs Prescribed to Children Are Safe and Effective.

[10] Center for Drug Evaluation and Research. How to comply with the Pediatric Research Equity Act [Internet]. FDA. 2005**.**

[11] Center for Drug Evaluation and Research. Qualifying for pediatric exclusivity under Section 505A of the federal [Internet]. FDA. 2022.

[12] Pediatric Research Equity Act of 2003; Proceedings of 108th Congress of the United States of America; Washington, D.C., USA. 7 January 2003;

[13] European Medicines Agency The European paediatric initiative: History of the Paediatric Regulation (EMEA/17967/04 Rev 1). 2010**.**

[14] National Institutes of Health (NIH). RePORT—RePORTER—Search Term "Pedriatic". Available online: (accessed on.

[15] European Medicines Agency ICH Topic E11: Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population (CPMP/ICH/2711/99). 2010.

[16] Official Journal of the European Communities. Council Resolution of 14 December 2000 on paediatric medicinal products (2001/C 17/01). 2010.

[17] European Medicines Agency Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO) (EMEA/537415/2008).

[18] Faulkner B, Delgado-Charro MB: Cardiovascular Paediatric Medicines Development: Have Paediatric Investigation Plans Lost Heart? Pharmaceutics. 2020, 12:1176. 10.3390/pharmaceutics12121176

[19] Official Journal of the European Union. Communication from the Commission: Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies (2008/C 234/01).

[20] Paediatric Team, Scientific Advice, Paediatrics & Orphan Drugs

Sector, European Medicines Agency The Paediatric Regulation (Presentation).

[21] Official Journal of the European Union. REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.

[22] Paediatric-use marketing authorisations - European Medicines Agency [Internet]. [cited 2023 Dec 3].

[23] Mahmood I.: Pediatric Pharmacology and Pharmacokinetics. Pine House Publisher; Rockville, MD, USA: 2008. p. 184 ff.

[24] Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency Reflection paper: formulations of choice for the paediatric population (EMEA/CHMP/PEG/194810/2005).

[25] WHO. Development of paediatric medicines: Points to Consider in pharmaceutical development.

[26] Smith L, Leggett C, Borg C: Administration of medicines to children: a practical guide. Aust Prescr. 2022, 45:188–92. 10.18773/austprescr.2022.067

[27] Galande AD, Khurana NA, Mutalik S: Pediatric dosage forms—challenges and recent developments: A critical review. J Appl Pharm Sci. 2020, 155–66. 10.7324/JAPS.2020.10718

[28] Khan D, Kirby D, Bryson S, Shah M, Rahman Mohammed A: Paediatric specific dosage forms: Patient and formulation considerations. International Journal of Pharmaceutics. 2022, 616:121501. 10.1016/j.ijpharm.2022.121501

[29] Shelley S: Pediatric drug market finds its own pathway. Pharmaceutical Commerce. New York, NY, 2015.

[30] Rademaker CMA, van Dijk L, Mantel-Teeuwisse. AK. IV: Pediatric drug formulations: a review of challenges and Progress. Pediatrics, 2014; 134(2):366.

[31] Beauchamp T, Childress J.: Principles of Biomedical Ethics. 7th ed. New York: Oxford University Press; 2013.

[32] Howie SR.: Blood sample volumes in child health research: Review of

safe limits. Bulletin of the World Health Organization. 2011;89:46-53.

[33] EudraLex. Ethical Considerations for Clinical Trials on Medicinal Products Conducted with Minors, Revision 1.

[34] Wiener, A.; Shudler, M.; Levit, A.; Niv, MY. BitterDB: A Database of Bitter Compounds. Nucleic Acids Research. January 2012.

[35] Walsh, J.; Cram, A.; Woertz, K.; Breitkreutz, J.; Winzenburg, G.; Turner, R.; Tuleu, C.. European Formulation Initiative. Playing Hide and Seek with Poorly Tasting Paediatric Medicines: Do Not Forget the Excipients. Adv Drug Deliv Rev. 2014 Jun;73:14-3.